Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

March 10, 2022

Study Completion Date

March 10, 2022

Conditions
COVID-19Venous ThromboembolismArterial Thrombosis
Interventions
DRUG

Unfractionated Heparin IV

Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an aPTT of 1.5-2.5 times the control as per institutional therapeutic target for treatment of VTE

DRUG

Enoxaparin 1 mg/kg

Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours

DRUG

Clopidogrel

Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days

DRUG

Unfractionated heparin SC

Heparin 5,000 units administered subcutaneous three times daily

DRUG

Enoxaparin 40 mg SC

Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl\<30 ml/min)

Trial Locations (1)

02459

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

The TIMI Study Group

OTHER

NCT04409834 - Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial | Biotech Hunter | Biotech Hunter